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Abstract Aminoglycoside antibiotics, in particular genta-
micin and tobramycin, are still commonly used in paediat-
ric clinical practice. These drugs cause nephrotoxicity,
which particularly affects the proximal tubule epithelial
cells due to selective endocytosis and accumulation of ami-
noglycosides via the multi-ligand receptor megalin. Recent
epidemiological studies, using more widely accepted defi-
nitions of acute kidney injury (AKI), have suggested that
AKI may occur in between 20 and 33 % of children exposed
to aminoglycosides. A consensus set of phenotypic criteria
for aminoglycoside-induced nephrotoxicity have recently
been published. These are specifically designed to provide
robust phenotyping for pharmacogenomic studies, but they
can pave the way for standardisation for all clinical studies.
Novel renal biomarkers, in particular kidney injury mole-
cule-1, identify aminoglycoside-induced proximal tubular
injury earlier than traditional markers and have shown
promise in observational studies. Further studies need to
demonstrate a clear association with clinically relevant out-
comes to inform translation into clinical practice. Extended
interval dosing of aminoglycosides results in a reduction in
nephrotoxicity, but its use needs to become more wide-
spread. Inhibition of megalin-mediated endocytosis by
statins represents a novel approach to the prevention of
aminoglycoside-induced nephrotoxicity which is currently
being evaluated in a clinical trial. Recommendations for
future directions are provided.
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Introduction
The first aminoglycoside, streptomycin, was introduced into
clinical practice in 1944, and has since been followed bymany
drugs of this class [1]. The most common of these in clinical
practice are gentamicin and tobramycin. The aminoglycosides
are particularly active against aerobic Gram-negative bacteria,
including Enterobacteriaceae and Pseudomonas. Clinically,
aminoglycosides may be used to provide targeted therapy,
such as for the treatment of pulmonary exacerbations in chil-
dren with cystic fibrosis colonised with Pseudomonas
aeruginosa. They are also used for the empirical treatment
of suspected systemic sepsis, where they are given in combi-
nation with other antibiotics (such as gylcopeptide or beta-
lactam antibiotics) to provide broad spectrum coverage of
Gram-positive and Gram-negative bacterial species.
Nephrotoxicity, one of the most important adverse effects
linked to aminoglycoside exposure, is associated with a vary-
ing degree of renal tubular dysfunction that may in the most
severely affected patients lead to non-oliguric acute kidney
injury (AKI) [1]. This review has three aims: first, to evaluate
what is currently known about aminoglycoside nephrotoxicity
in children; second, to describe recent advances in the field,
including novel diagnostics and therapeutic approaches; third,
to provide recommendations on future directions for research.
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Mechanisms of aminoglycoside-induced
nephrotoxicity
Aminoglycoside-induced nephrotoxicity is characterised by
selective targeting of the proximal tubule epithelial cells with-
in the renal cortex. Approximately 5 % of the administered
dose accumulates within these cells after glomerular filtration
[2]. Endocytosis via the multi-ligand receptor megalin has
been demonstrated to be the principal pathway for this accu-
mulation: megalin knock-out mice do not exhibit renal accu-
mulation of aminoglycosides [3]. Megalin is a ligand for nu-
merous low-molecular-weight proteins (including albumin,
vitamin D-binding protein, retinol-binding protein, α1-
microglobulin and β2-microglobulin) and is highly expressed
by proximal tubule epithelial cells [4, 5], explaining the cell-
and tissue-specificity of this toxicity.
Once inside the cell, aminoglycosides accumulate within
lysosomes [6], the Golgi apparatus and endoplasmic reticulum
(ER) [7], binding to phospholipids and inhibiting phospholi-
pase activity, which results in lysosomal phospholipidosis [6,
8]. At some unknown threshold concentration of aminoglyco-
side, leakage occurs from the lysosomal structures into the cy-
toplasm [9]. Cytoplasmic aminoglycoside then acts both direct-
ly and indirectly on the mitochondria, activating the intrinsic
pathway of apoptosis via cytochrome c [10] which in turn leads
to the disruption of electron transport and ATP production and
the formation of reactive oxygen species [8]. Lysosomal ca-
thepsins, released into the cytoplasm, also activate the intrinsic
apoptotic pathway [11] and, in higher concentrations, may
cause necrosis [12]. In the ER, aminoglycosides inhibit protein
synthesis and associated ER functions, resulting in ER stress
and apoptosis via calpain and caspase 12 [13].
The reasons for inter-individual variability in susceptibility
to aminoglycoside-induced nephrotoxicity are not clear. In
particular, it is not known whether there are genetic factors
which increase susceptibility, as has been reported for
aminoglycoside-related hearing loss [14]. No genome-wide
studies have been undertaken in this area.
It can be hypothesised from the literature that muta-
tions resulting in megalin deficiency would be protective,
as in megalin knock-out mice [3]. Other proteins also play
a role in the pathway of megalin-mediated endocytosis.
For example, the CIC-5 protein, which is defective in
Dent’s disease, is involved in megalin trafficking [15].
In their study on renal accumulation of aminoglycoside
in CIC-5 knockout mice compared to controls, Raggi
et al. observed that there was an 85 % reduction in gen-
tamicin accumulation in the knockout mice [15]. The
same group also demonstrated a 15 % decrease in genta-
micin accumulation in mice with defective CFTR, the
gene affected in cystic fibrosis, and hypothesised that
CFTR may play a role in the pathway of megalin-
mediated endocytosis [15]. These results suggest that a
genetic variant which impairs the megalin-mediated up-
take pathway would therefore also provide some protec-
tion against aminoglycoside-induced nephrotoxicity.
However, no human studies have as yet investigated this
proposal.
Defining aminoglycoside-induced nephrotoxicity
A key difficulty in establishing the epidemiology of drug-
induced kidney injury, including that caused by aminogly-
cosides, has been the absence of consensus criteria for
diagnosing kidney damage. There are a number of classi-
fication systems for classifying AKI in children, of which
the best validated are the paediatric-modified RIFLE
(pRIFLE) criteria [16, 17] and the Acute Kidney Injury
Network (AKIN) criteria [18]. The pRIFLE criteria de-
pend on using estimated creatinine clearance, while the
AKIN criteria are based on measured serum creatinine
(Table 1). pRIFLE criteria seem to be the more sensitive
of the two classification systems, but the AKIN criteria
have a stronger association with poor outcomes, suggest-
ing that they may be more specific [19, 20]. More recent-
ly, the Kidney Disease: Improving Global Outcomes
(KDIGO) clinical practice guideline for AKI [21] has
attempted to develop consensus (Table 1).
A standardised set of phenotypic criteria for drug-
induced kidney disease (DIKD) has also recently been
published by Mehta et al. [22]. This work was initiated
by the International Serious Adverse Event Consortium,
following on from previous work by this group in devel-
oping phenotypic criteria for other drug-induced adverse
events [23]. Although the initial purpose of these criteria
is to provide clear phenotypes for genetic studies of
DIKD, they may also provide a consistent framework
for all research in DIKD. Four phenotypes of DIKD have
been proposed:
& AKI
& Glomerular disorder
& Tubular disorder
& Nephrolithiasis/crystalluria
In relation to aminoglycoside-induced nephrotoxicity,
the authors have suggested that it should be characterised
by the AKI phenotype. The criteria for this phenotype are
summarised in Table 2. An issue which also needs to be
considered in a child with AKI is causality, i.e. whether
the AKI is due to the infection for which the aminogly-
coside was prescribed, or due to the drug per se. As there
are no specific diagnostic tests for aminoglycoside neph-
rotoxicity, standardised causality assessment tools should
be used, of which many have been described [24].
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Epidemiology of aminoglycoside-induced
nephrotoxicity in children
Children
Until recently, little data have been available documenting the
incidence of aminoglycoside-induced nephrotoxicity in chil-
dren, in part due to the lack of an accepted definition for AKI.
However, following the recent advent of more widely accept-
ed definitions of AKI in children, a number of studies have
begun to address this question.
A retrospective cohort study at a tertiary children’s hospital
in the USA used the pRIFLE criteria and the AKIN Staging
definition to define aminoglycoside-induced nephrotoxicity
[19]. Of the 557 children who received aminoglycoside treat-
ment for ≥5 days over the year of the study, the AKI rate was
33 and 20 % using the pRIFLE and AKIN criteria, respective-
ly. AKI was associated with longer hospital stay and higher
total hospital costs. The authors reported that whilst pRIFLE
was more sensitive for the identification of AKI, AKIN was
more strongly associated with patient outcomes.
Another factor limiting the quality of epidemiological data
available is inconsistency among monitoring practices. In a
prospective study of all admissions involving aminoglycoside
exposure for ≥3 days at a tertiary paediatric centre in the USA,
daily measurement of serum creatinine was used to monitor
for AKI. AKI, defined by the pRIFLE criteria, was identified
in 25 % of unique patients exposed to aminoglycosides and
during 31 % of admission episodes [25].
Neonates
Gentamicin is the drugmost commonly prescribed to neonates
in the UK [26]. An American study found that 57.5 % of all
neonates discharged from the neonate intensive care unit had
received treatment with gentamicin [27]. The UK National
Institute of Health and Care Excellence (NICE) guidelines
recommend the use of gentamicin (in combination with a pen-
icillin) for first line therapy in neonates with suspected early-
onset sepsis [28]. Despite its widespread use, there are a pau-
city of data quantifying gentamicin-induced nephrotoxicity in
neonates [29].
A retrospective study of nephrotoxin exposure in preterm
neonates at one U.S. centre documented gentamicin exposure
in 86.0 % of the 107 neonates [30]. In this cohort, 26.2 %
developed AKI. Whilst this study cannot demonstrate
Table 1 Paediatric acute kidney injury definitions
Paediatric Risk, Injury, Failure, Loss,
End-Stage Kidney Disease (pRIFLE) system
Acute Kidney Injury Network (AKIN) guideline Kidney Disease: Improving
Global Outcomes (KDIGO) guideline
AKI severity Estimated
creatinine
clearance
Urine output AKI
severi-
ty
Serum creatinine Urine output AKI
severi-
ty
Serum creatinine Urine output
‘Risk’ (R) Decrease by
25 %
<0.5 ml/kg/h
for 8 h
Stage 1 ≥0.3 mg/dl
(26.5 μmol/L) rise
OR
Increase to 1.5–1.99×
baseline
<0.5 ml/kg/h
for >6 h
Stage 1 1.5–1.9× baseline
OR
≥0.3 mg/dl
(≥26.5 μmol/l)
increase
<0.5 ml/kg/h for
6–12 h
‘Injury’ (I) Decrease by
50 %
<0.5 ml/kg/h
for 16 h
Stage 2 Rise to ≥2–2.99×
baseline
<0.5 ml/kg/h
for >12 h
Stage 2 2.0–2.9× baseline <0.5 ml/kg/h for
≥12 h
‘Failure’ (F) Decrease by
75 %
OR
Creatinine
clearance of
<35 ml/-
min/1.73 m2
<0.3 ml/kg/h
for 24 h
OR
anuria for 12 h
Stage 3 Rise to ≥3× baseline
OR
≥4 mg/dl
(353.6 μmol/L) rise
with an acute rise of
at least 0.5 mg/dl
(44 μmol/L)
<0.3 ml/kg/h
for 24 h
OR
Anuria for 12 h
Stage 3 3.0× baseline
OR
Increase in serum
creatinine to
≥4.0 mg/dl
(≥353.6 μmol/l)
OR
Initiation of renal
replacement
therapy
OR
In patients aged
<18 years, decrease
in estimated
glomerular
filtration rate to
<35 ml/min per
1.73 m2
<0.3 ml/kg/h for
≥24 h
OR
Anuria for ≥12 h
The paediatric acute kidney injury definitions presented in this table are adapted from Akcan-Arika [16] and Kellum et al. [21]
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causation, it does highlight the potential adverse impact of
exposure to nephrotoxins in this population. A recent narrative
review included ten studies of gentamicin use in neonates,
where nephrotoxicity was assessed using plasma creatinine
[31]. Interestingly, seven of these studies reported no nephro-
toxicity, while the remaining three reported various rates, the
maximum being 27 % [32]. This wide variation in rates again
highlights the previous lack of standardised criteria for diag-
nosing aminoglycoside nephrotoxicity.
Children with cystic fibrosis
Cystic fibrosis (CF) is an autosomal recessive life-limiting
disease which affects around 9000 people in the UK alone
[33]. The disease is characterised by the accumulation of thick
secretions in the airways of the lungs that lead to reduced
activity of the mucociliary escalator and predispose to second-
ary bacterial infection and pulmonary colonisation, often by
resistant organisms, in particular Pseudomonas aeruginosa.
Approximately 25 % of children with CF aged 12–15 years
have chronic pulmonary infection with P. aeruginosa; this
infection rate rises to 40 % by 16–19 years of age [33].
Aminoglycosides have good efficacy against P. aeruginosa
and are commonly used intravenously to treat pulmonary ex-
acerbations in CF in combination with a beta-lactam antibiot-
ic, such as ceftazidime. Treatment courses usually last for
2 weeks, and patients may have multiple courses of treatment
throughout their lifetime.
A UK national survey of AKI in patients with CF found 24
cases between 1997 and 2004 [34]; of these 88 % of patients
were receiving an aminoglycoside at the time of developing
AKI, or within the previous week. Identification of AKI relied
on physician report and did not use standardised criteria—
rather the AKI was defined as ‘raised plasma creatinine for
age with or without oliguria’ [34]. A follow-on case–control
study identified an 80-fold increase in the risk of AKI if CF
patients received an aminoglycoside within the preceding
week [35]. AKI was associated with significant acute morbid-
ity, with 54 % requiring dialysis [34].
The impact of daily monitoring of serum creatinine during
treatment with aminoglycosides in children with CF has been
assessed in a retrospective study in a tertiary paediatric centre
in the USA [36]. AKI was defined as a rise in serum creatinine
by ≥0.3 mg/dl (26.5 μmol/L) within 48 h, or a 1.5-fold in-
crease in the baseline serum creatinine level. Daily monitoring
not only led to more cases of AKI being identified (in 21 of
103 courses, 20 %), but also an earlier identification of AKI.
The authors of this study suggested that daily monitoring also
led to changes in management (including increased use of
once-daily dosing of aminoglycosides and intravenous (IV)
fluids, reduced use of concomitant nephrotoxins and shorter
courses of aminoglycosides) in an attempt to prevent or ame-
liorate AKI, although a randomised trial would be required to
assess whether there was any impact on patient outcomes. In a
second study, which had a case–control design, the same
group identified that of the 593 admissions in which children
were treated with an aminoglycoside for an exacerbation of
CF [37], there were 82 cases of AKI (14 %) which they felt
were aminoglycoside-induced.
Long-term outcomes of aminoglycoside-induced
nephrotoxicity
Nephrotoxin-associated AKI may lead to chronic kidney dis-
ease (CKD) [38]. In a retrospective cohort study, children who
Table 2 Suggested phenotypic
criteria for drug-induced acute
kidney injury, including that
caused by aminoglycosides
Primary criteria Secondary criteria
• Rise in serum creatinine that presents as or
progresses to stage 2 (KDIGO) 2–2.9×
reference serum creatinine or higher
• If child has a baseline serum creatinine of <0.5 mg/dl
(44 μmol/L), must double serum creatinine
to get to at least 0.5 mg/dl (44 μmol/L) or above
OR
• Decline by at least 50 % from peak serum creatinine
over 7 days in relationship to change in drug-dosing
adjustment or discontinuation within 2 weeks
• Oliguric <0.5 ml/kg per hour
for 12 h (KDIGO stage 2)
• Non-oliguric >1 ml/kg per hour
for 24 h (paediatrics)
• Urinalysis findings: granular and
muddy casts consistent with acute
tubular necrosis, urinary eosinophils,
proteinuria
• Fractional excretion of sodium of >1 %
• Negative ultrasound findings
• Positive gallium scan for acute interstitial
nephritis
• Clinical symptoms for acute interstitial
nephritis: fever, rash and joint pains
The phenotypic criteria for drug-induced acute kidney injury presented in this table are adapted fromMehta et al.
[22]
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developed AKI (using pRIFLE criteria) associated with
nephrotoxin exposure (≥3 days of aminoglycosides or ≥3
nephrotoxins simultaneously for 1 day) had a relative
risk of 3.84 [95 % confidence interval (CI) 1.57–9.40,
P <0.05] for developing one or more signs of CKD
[reduced estimated glomerular filtration rate (GFR),
hyperfiltration, proteinuria, or hypertension] at 6 months
compared to controls (nephrotoxin exposure, but no
AKI) [38].
The long-term effects of multiple exposures to amino-
glycosides are less clear. In a cohort of adults with CF
from Liverpool, chronic renal impairment (as measured
by reduced creatinine clearance) was reported in 31–
42 % of adult CF patients (depending on definition) and
was associated with cumulative aminoglycoside exposure
(P= 0.0055) [39]. This effect was exacerbated by the con-
comitant use of intravenous (IV) colistin, although IV
colistin alone did not have an impact on renal function
[39]. A previous, slightly smaller study in a Danish CF
centre using tobramycin found no association between
previous tobramycin exposure and measured creatinine
clearance [40].
Biomarkers of aminoglycoside-induced
nephrotoxicity
Existing approaches
The traditional indicator of AKI is a rise in serum creat-
inine concentration, which forms the basis of all current
AKI definitions (Table 1). A rise in serum creatinine con-
centration as an indicator of GFR has long been
established in clinical practice and is simple to measure;
in addition, the test is very widely available. However, an
elevation of serum creatinine is a delayed response, with
levels rising significantly above baseline only when 25–
50 % of renal function has been lost [41]. Reliance upon
this measurement means that AKI is frequently not iden-
tified early and that the degree of damage may be
underestimated [42]. Furthermore, an increased level of
serum creatinine is a marker of glomerular filtration and
not an indicator of damage at other sites in the nephron.
Interpretation is made more difficult by the variation in
the production of creatinine, which depends on age, sex
and weight (in particular muscle mass). Interpretation is
also difficult in the newborn, in whom serum creatinine
initially reflects maternal values.
Potential of novel biomarkers
Early identification of nephrotoxicity requires a sensitive
marker that can be quantified earlier than is the case with
currently used indicators. Identification of aminoglycoside-
induced nephrotoxicity also requires a biomarker that is spe-
cific for the resulting proximal tubule injury, which would
allow for early treatment adjustment, intervention and the
avoidance of further injury.
The Predictive Safety Testing Consortium (PSTC), a
collaboration of academic, industry (both pharmaceutical
and biotechnology companies) and regulatory [the US
Food and Drug Agency (FDA) and the European
Medicines Agency (EMA)] partners, was established to
expedite the qualification of renal biomarkers of nephro-
toxicity. The work of the PSTC has led to the qualifica-
tion of seven renal biomarkers for pre-clinical use by the
FDA, EMA and Japanese Pharmaceuticals and Medical
Devices Agency (PMDA), namely, kidney injury
molecule-1 (KIM-1), albumin, total protein, β2-micro-
globulin, cystatin C, clusterin and trefoil factor-3 [43].
Amongst those approved by the FDA, EMA and
PMDA, only KIM-1 is specific for the proximal tubule.
Albumin, β2-microglobulin, and cystatin C may reflect
damage to both the proximal tubule and the glomerulus,
whereas clusterin may reflect damage to both the proxi-
mal and distal tubule [44]. Total protein reflects glomer-
ular injury [44], and trefoil factor-3 is expressed in the
collecting duct [45]. The albumin/creatinine ratio is
widely utilised clinically as a marker of renal disease
and response to treatment. However, its urinary concen-
tration may be altered by both changes in glomerular
permeability and tubular reabsorption. Furthermore, the
concentration of albumin may be increased by additional
factors, including fever, exercise, dehydration, diabetes
and hypertension, thereby limiting its specificity for
AKI and, in particular, for aminoglycoside-induced neph-
rotoxicity [44]. Of those renal biomarkers which have
not been qualified through the work of the PSTC, neu-
trophil gelatinase-associated lipocalin (NGAL) and N-
acetyl-β-D-glucosaminidase (NAG) have received the
most interest as biomarkers of proximal tubular injury.
The potential of KIM-1, NGAL and NAG as biomarkers
of aminoglycoside-induced nephrotoxicity is detailed in
Table 3.
In line with preclinical data [46], KIM-1 outperformed
other biomarkers (NGAL, NAG and serum creatinine) in
the identification of the potential for aminoglycoside-
induced nephrotoxicity in preterm neonates [47]. In chil-
dren with CF, urinary KIM-1 concentration was signifi-
cantly correlated with the number of previous courses of
aminoglycosides (r= 0.35, P = 0.012) [48]. Our group has
replicated this finding in a UK paediatric CF cohort (R=
0.70, P <0.002), published in abstract form [49]. This
work also identified acute elevation in KIM-1 concentra-
tions during aminoglycoside exposure [49], which has al-
so been reported elsewhere in abstract form [50].
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Preventing aminoglycoside-induced nephrotoxicity
Existing approaches
Choice of aminoglycoside
The choice of aminoglycoside is important in reducing
nephrotoxicity. The following rank order of nephrotoxici-
ty has been reported, from most toxic to least toxic: neo-
mycin > gentamicin ≥ tobramycin ≥ amikacin ≥ netilmicin
> streptomycin [1]. However, it is noted that the differ-
ences from gentamicin through to netilmicin may be small
and that the results in clinical trials are inconsistent.
A meta-analysis of 43 randomised trials in both adults
and children comparing the efficacy and toxicity of ami-
noglycosides calculated pooled odds ratios for the
potential of the different drugs to cause nephrotoxicity
[51]. A weakness of this approach is that the studies used
different definitions of nephrotoxicity, which brings into
question the validity of combining different studies.
However, the authors of the meta-analysis reported that
tobramycin demonstrated less nephrotoxicity than genta-
micin (odds ratio 0.64, 95 % CI 0.42–0.97).
In a case–control study of paediatric and adult patients
with CF, gentamicin exposure in the previous year was
associated with AKI (19/24 cases vs. 1/42 controls; P <
0.001, odds ratio incalculable), whereas tobramycin was
not (9/24 cases vs. 16/42 controls, P = 0.9, odds ratio 1.0,
95 % CI 0.3–2.6) [35]. Moreover, gentamicin resistance
has been reported in the majority of P. aeruginosa isolates
from CF patients [52]. There has therefore been a shift
away from using gentamicin and towards tobramycin, to
Table 3 Comparative description
of three novel urinary biomarkers
and their utility in
aminoglycoside-induced
nephrotoxicity
Biomarker Description Utility in aminoglycoside-
induced nephrotoxicity
Comments
Kidney Injury
Molecule-1
(KIM-1)
Cell membrane
glycoprotein
upregulated by proximal
tubule epithelial cells in
response to toxicity [73]
Confers a phagocytic
phenotype [74]
Outperforms, with respect
to sensitivity and
specificity, traditional
and novel biomarkers of
AKI (serum creatinine,
blood urea nitrogen, and
NAG), as confirmed by
histopathology in animal
models [46]
Early diagnostic marker for
AKI and predictor of
mortality risk [75]
Elevated during
aminoglycoside
exposure in preterm
neonates [47] and
children with CF [49,
50]
Specific to proximal
tubule
Outperforms other
biomarkers in
pre-clinical models
of
aminoglycoside--
induced
nephrotoxicity
Neutrophil
Gelatinase-associ-
ated Lipocalin
(NGAL)
25-kDa protein expressed
by kidney epithelial cells
(and other tissues, as
well as neutrophils) [76]
Upregulated in response to
nephrotoxins in mouse
models [77]
Sensitive early predictor for
AKI [75]
Elevated during
aminoglycoside
exposure in preterm
neonates [47]
Levels elevated in
sepsis/inflammation
[78] which may
limit specificity
N-acetyl-β-D-gluco-
saminidase (NAG)
130- to 140-kDa lysosomal
enzyme specific to
proximal tubule
epithelial cells [79]
Widely used in pre-clinical
and clinical studies of
aminoglycoside-induced
nephrotoxicity [80]
Elevated during
aminoglycoside
exposure in preterm
neonates [47]
Outperformed by
KIM-1 in
pre-clinical models
of
aminoglycoside--
induced
nephrotoxicity
AKI, Acute kidney injury; CF, cystic fibrosis
Pediatr Nephrol
which P. aeruginosa is more widely sensitive, in the man-
agement of acute exacerbations of CF.
Extended interval dosing
In theory, extended interval dosing of aminoglycosides may
be safer for the kidneys. A higher single dose may result in
saturation of megalin-mediated uptake of aminoglycoside in
the proximal tubule, resulting in a greater percentage of the
aminoglycoside being excreted in the urine [53]. The TOPIC
study was a well-powered clinical trial comparing one versus
three daily doses of IV tobramycin for pulmonary exacerba-
tions in adults and children with CF [54]. The authors of this
study demonstrated an equivalent efficacy of both regimens
using the change in forced expiratory volume in 1 s (FEV1) as
their primary outcome measure. In children, there was a 3.7 %
increase in serum creatinine with three daily doses compared
with a 4.5% decrease with a single daily dose of tobramycin, a
difference which was statistically significant. This finding was
supported by measurements of NAG pre-treatment and after
14 days of tobramycin: the increase in urinary NAGwas 33%
less with once-daily dosing compared to the three daily doses
administered to the treatment group (P = 0.049 in adults and
children, and P = 0.02 in children alone). With evidence of
equal efficacy, and reduced nephrotoxicity, this study has led
to widespread adoption of once-daily dosing of tobramycin
(10 mg/kg) and a move away from dosing three times daily
in children with CF. However, the uptake of extended interval
dosing is not universal: a recent survey in the USA reported
that extended interval dosing of aminoglycosides was used in
63 % of hospitals [55].
A meta-analysis of studies comparing once-daily with
multiple-daily doses of aminoglycosides in children has also
been undertaken [56]. However, definitions of toxicity were
not consistent across the studies. The authors of the meta-
analysis defined primary nephrotoxicity as ‘a rise in serum
creatinine or decrease in creatinine clearance with thresholds
as defined in each study’. They found that 1.6 % of children
experienced primary nephrotoxicity in both the once-daily and
multiple-daily dosing groups [56].
Therapeutic drug monitoring
Therapeutic drug monitoring is felt to be helpful for monitor-
ing both efficacy and toxicity. Elevated trough levels suggest
reduced renal clearance of aminoglycoside. This may reflect
pre-existing renal dysfunction, but is also considered to be a
risk factor for developing nephrotoxicity: for example, several
adults and children with CF who developed AKI had trough
tobramycin levels above 2 mg/L [34]. There is no consistent
guidance on the optimal regimen for therapeutic drug moni-
toring in either multiple-daily or extended interval dosing, and
practice thus varies widely. For instance, UK CF guidelines
recommend that levels measured 18 h after the previous dose
(with a single daily dose) should be <1 mg/L [57]. U.S. CF
guidance recommends levels taken between 9 and 11 hour
post-dose should be undetectable [58]. With a peak, and an-
other level 6–8 h post-dose, it is possible to use pharmacoki-
netic principles to adjust dosing to a target area under the
curve (AUC) [59]. This approach is used in some centres in
both adults and children, but there is little evidence to define
what the optimum AUC should be to maximise the benefit–
risk ratio [59].
Nebulised aminoglycosides
Nebulised aminoglycosides (especially tobramycin) have be-
come increasingly widely used in CF. They tend to be used
over the long term in those patients with P. aeruginosa
resulting in an improvement in FEV1 and a reduction in time
spent in hospital in both adults and children [60]. The per-
ceived benefits are that the antibiotic is delivered directly to
the desired site of action and that it is therefore felt to be
possible to deliver high local concentrations, with reduced
systemic exposure. However, inhaled tobramycin is systemi-
cally absorbed [61], and AKI associated with nebulised
tobramycin has been reported [62]. The incidence of nephro-
toxicity is thought to be lower than that with IV aminoglyco-
sides, but this has not been investigated in detail.
Novel approaches
Daily monitoring of serum creatinine
In the NINJA study (Nephrotoxic Injury Negated by Just-in-
time Action) systematic screening of electronic health records
was instituted to identify children receiving IV aminoglyco-
sides for ≥3 days or ≥3 simultaneous nephrotoxins. In the
patients enrolled in this study, daily monitoring of serum cre-
atinine was recommended. The mean weekly AKI rate was
25.5 % for nephrotoxin-exposed patients using the pRIFLE
criteria [25]. A 42 % reduction in AKI intensity (from 33.6 to
19.5 days/100 exposure days) was reported during 1 year of
implementation of the screening programme [25]. The results
of a follow-up analysis of this project after 3 years of imple-
mentation revealed that there had been a 38 % reduction in
exposure to nephrotoxic medications (11.63 to 7.24
exposures/1000 patient days), and a 64 % reduction in the
AKI rate (2.96 to 1.06 episodes/1000 patient days) [63].
Time of dosing
A recently published, open label, randomised controlled trial
(RCT) investigated the impact of time of day on the pharma-
cokinetics and nephrotoxicity of IV tobramycin in 18 children
with CF [64]. Children received IV tobramycin at either 0800
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or 2000 hours. Nephrotoxicity was assessed using a panel of
urinary biomarkers, including KIM-1, cystatin C, NGAL,
interleukin-18 and NAG. Urine was collected at baseline and
at the end of a 14-day treatment course. There was no differ-
ence in renal clearance between the two groups. Of all the
biomarkers measured, only KIM-1 was different between the
two groups, with a significantly greater increase in the evening
group compared to the morning group (P < 0.05), suggesting
an increased risk of nephrotoxicity with evening administra-
tion. The authors postulated that this difference was due to the
impact of established diurnal rhythms on the pharmacokinet-
ics and pharmacodynamics of tobramycin, but this hypothesis
needs further investigation. The possibility that morning ad-
ministration of aminoglycosides may be safer than evening
administration deserves further investigation in a larger RCT.
Pharmacological interventions
A large number of drugs have been proposed to have the
potential to inhibit aminoglycoside-induced nephrotoxicity
[65]. However, we are only aware of two which have been
investigated in humans.
One small RCT assessed the calcium channel blocker ni-
fedipine in adult patients receiving gentamicin for the treat-
ment of upper urinary tract infection [66]. It was a small study,
with a total of 32 participants. The primary outcome measure
was change in creatinine clearance, and the results demon-
strated an improvement in creatinine clearance in the interven-
tion group, with a deterioration in the placebo group.
Unfortunately, the trial had methodological limitations, and
it is difficult to draw conclusions as to whether nifedipine
had a true positive impact. Indeed, it is possible that the effect
on the GFR was a direct effect of the nifedipine itself, second-
ary to vasodilation of the afferent arteriole, leading to in-
creased glomerular perfusion, rather than due to any inhibition
of gentamicin-induced nephrotoxicity. To our knowledge,
there have been no further studies of calcium channel blockers
in humans, while animal studies have not consistently shown
that aminoglycoside-induced nephrotoxicity can be prevented
by calcium-channel blockers [65].
A randomised crossover study of fosfomycin, an infre-
quently used broad-spectrum phosphonic acid antibiotic, in
eight adult patients with CF receiving tobramycin and colistin
showed that there was a small reduction in proteinuria with
concomitant fosfomycin treatment; however, there was no ef-
fect on serum creatinine [67]. The size of this study is a lim-
itation, and it has only been published in abstract form.
Inhibition of megalin-mediated endocytosis
of aminoglycosides
Inhibition of megalin-mediated endocytosis, the primary path-
way for the renal accumulation of aminoglycosides, has been
proposed as a potential preventive strategy. Indeed, known
megalin substrates, including cytochrome c and cationic pep-
tide fragments, have demonstrated dose-dependent competi-
tive inhibition of megalin-mediated uptake of gentamicin
in vitro and inhibition of nephrotoxicity in vivo (rat and
mouse) [68]. However, blockade of megalin with endogenous
peptides does not provide a viable therapeutic strategy in
humans as such peptides may be unstable and would need to
be administered parenterally; in addition, there may be a risk
of immunogenicity.
More promising are the results showing that statins can
inhibit megalin-mediated endocytosis in vitro [69, 70]. In
keeping with this, statins (simvastatin, pravastatin and
rosuvastatin) inhibited gentamicin accumulation and cytotox-
icity in a dose-dependent manner in an in vitro proximal tu-
bule model [5]. Inhibition of gentamicin-induced nephrotoxi-
city by simvastatin has also been demonstrated in rats [71, 72].
We are currently investigating this mechanism in humans
for the first time through a phase IIa randomised, controlled,
clinical trial of rosuvastatin for the prevention of
aminoglycoside-induced nephrotoxicity in children with CF
(The PROteKT study; EudraCT 2014-002387-32, UKCRN
ID 16993, ISRCTN26104255).
Future directions
It is only recently, with the advent of standardised definitions
of AKI, that studies have begun to shed more light on the
epidemiology of aminoglycoside-induced nephrotoxicity.
Large observational cohort studies of both paediatric and adult
patients being treated with aminoglycosides are needed.
However, the design of such studies is important. First, these
would need to use a standardised definition of AKI [such as
the KDIGO guideline (Table 1)] alongside standardised phe-
notypic criteria for aminoglycoside-induced nephrotoxicity
(Table 2) [22]. Second, they should include baseline and serial
measurements of novel renal biomarkers, in particular KIM-1,
in order to assess the predictive value of these markers for
AKI. Third, DNA should be collected for pharmacogenomic
analyses. This approach will allow for the description of the
size of the problem using accepted definitions, an assessment
of the potential clinical utility of novel biomarkers and the
identification of risk factors for the development of
aminoglycoside-induced nephrotoxicity, including genetic
factors.
The potential of novel, non-invasive, urinary biomarkers
has been described. KIM-1 shows promise as a biomarker of
acute and chronic proximal tubular injury associated with ex-
posure to aminoglycosides [47–50] and outperforms other
biomarkers in pre-clinical studies [46]. As described above,
demonstrating a clear association with clinically relevant out-
comes will inform future translation into clinical practice.
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Following this, further qualification of KIM-1, or any other
promising biomarker, would be required through novel study
designs (including RCT) where the measured biomarker con-
centrations are used to guide treatment decisions in patients
exposed to aminoglycosides.
The development of improved diagnostic tools must be
coupled with the development of further strategies to mini-
mise the nephrotoxic consequences of aminoglycosides. A
promising preventive strategy utilising statins has already
been described and is currently being assessed in childrenwith
CF, using KIM-1 as the primary outcome measure. If success-
ful, this intervention will require assessment in a large, phase
III RCT using a standardised definition of AKI as the primary
outcome measure in order to pave the way for widespread
clinical application.
Conclusion
Clinicians considering the use of aminoglycosides for the
treatment of infection in their patients will be well aware of
the potential for nephrotoxicity to occur with these antibiotics.
Despite changes to practice, such as extended interval dosing,
nephrotoxicity still occurs. Novel renal biomarkers, in partic-
ular KIM-1, may lead to the earlier identification of nephro-
toxicity, ultimately allowing for timely intervention to prevent
further kidney injury. Preventive strategies may ultimately
lead to further changes in clinical practice that significantly
improve the benefit–risk ratio of aminoglycosides which is
much needed in the current environment where the rise of
antimicrobial resistance poses a major threat to the global
population.
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